270 research outputs found
Role of transport performance on neuron cell morphology
The compartmental model is a basic tool for studying signal propagation in
neurons, and, if the model parameters are adequately defined, it can also be of
help in the study of electrical or fluid transport. Here we show that the input
resistance, in different networks which simulate the passive properties of
neurons, is the result of an interplay between the relevant conductances,
morphology and size. These results suggest that neurons must grow in such a way
that facilitates the current flow. We propose that power consumption is an
important factor by which neurons attain their final morphological appearance.Comment: 9 pages with 3 figures, submitted to Neuroscience Letter
Beyond Hebb: Exclusive-OR and Biological Learning
A learning algorithm for multilayer neural networks based on biologically
plausible mechanisms is studied. Motivated by findings in experimental
neurobiology, we consider synaptic averaging in the induction of plasticity
changes, which happen on a slower time scale than firing dynamics. This
mechanism is shown to enable learning of the exclusive-OR (XOR) problem without
the aid of error back-propagation, as well as to increase robustness of
learning in the presence of noise.Comment: 4 pages RevTeX, 2 figures PostScript, revised versio
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs
are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum
microRNA signature useful to predict cancer development. We focused on studying
the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs.
92 control individuals. Bioinformatic studies provide a microRNA signature, designated
as a predictor, based on the expression levels of five microRNAs. Then, we tested the
predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled
the overexpression and downregulation of proteins differently expressed in the serum of
breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate
cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer
patients from that of the control group. The tissue expression of miR-99a, miR-497,
miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival.
Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and
miR-451 was able to differentiate breast cancer patients from controls. The predictor was
validated in 20 new cases of breast cancer patients and tested in 60 volunteer women,
assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16
with a high content of CD44 protein in serum was found. Circulating microRNAs in serum
can represent biomarkers for cancer prediction. Their clinical relevance and the potential
use of the predictor here described are discussed
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM âEl Ălamo IIIâ retrospective study
Purpose: To determine the frequency of breast cancer (BC) patients with hereditary risk features in a wide retrospective cohort of patients in Spain. Methods: a retrospective analysis was conducted from 10, 638 BC patients diagnosed between 1998 and 2001 in the GEICAM registry âEl Ălamo IIIâ, dividing them into four groups according to modified ESMO and SEOM hereditary cancer risk criteria: Sporadic breast cancer group (R0); Individual risk group (IR); Familial risk group (FR); Individual and familial risk group (IFR) with both individual and familial risk criteria. Results: 7, 641 patients were evaluable. Of them, 2, 252 patients (29.5%) had at least one hereditary risk criteria, being subclassified in: FR 1.105 (14.5%), IR 970 (12.7%), IFR 177 (2.3%). There was a higher frequency of newly diagnosed metastatic patients in the IR group (5.1% vs 3.2%, p = 0.02). In contrast, in RO were lower proportion of big tumors (> T2) (43.8% vs 47.4%, p = 0.023), nodal involvement (43.4% vs 48.1%, p = 0.004) and lower histological grades (20.9% G3 for the R0 vs 29.8%) when compared to patients with any risk criteria. Conclusions: Almost three out of ten BC patients have at least one hereditary risk cancer feature that would warrant further genetic counseling. Patients with hereditary cancer risk seems to be diagnosed with worse prognosis factors
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. The integrated genomic and immune landscapes show that metastases propagate and evolve as communities of clones, reveal their predicted neo-antigen landscapes, and show that they can accumulate HLA loss of heterozygosity (LOH). The data further identify variable tumor microenvironments and reveal, through analyses of TÂ cell receptor repertoires, that adaptive immune responses appear to co-evolve with the metastatic genomes. These findings reveal in fine detail the landscapes of lethal metastatic breast cancer.CRUK
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93â1.04, P=0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89â1.06, P=0.5) mutation carriers. Conclusion: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out. A Osorio1, R L Milne2, G Pita3, P Peterlongo4,5, T Heikkinen6, J Simard7, G Chenevix-Trench8, A B Spurdle8, J Beesley8, X Chen8, S Healey8, KConFab9, S L Neuhausen10, Y C Ding10, F J Couch11,12, X Wang11, N Lindor13, S Manoukian4, M Barile14, A Viel15, L Tizzoni5,16, C I Szabo17, L Foretova18, M Zikan19, K Claes20, M H Greene21, P Mai21, G Rennert22, F Lejbkowicz22, O Barnett-Griness22, I L Andrulis23,24, H Ozcelik24, N Weerasooriya23, OCGN23, A-M Gerdes25, M Thomassen25, D G Cruger26, M A Caligo27, E Friedman28,29, B Kaufman28,29, Y Laitman28, S Cohen28, T Kontorovich28, R Gershoni-Baruch30, E Dagan31,32, H Jernström33, M S Askmalm34, B Arver35, B Malmer36, SWE-BRCA37, S M Domchek38, K L Nathanson38, J Brunet39, T RamĂłn y Cajal40, D Yannoukakos41, U Hamann42, HEBON37, F B L Hogervorst43, S Verhoef43, EB GĂłmez GarcĂa44,45, J T Wijnen46,47, A van den Ouweland48, EMBRACE37, D F Easton49, S Peock49, M Cook49, C T Oliver49, D Frost49, C Luccarini50, D G Evans51, F Lalloo51, R Eeles52, G Pichert53, J Cook54, S Hodgson55, P J Morrison56, F Douglas57, A K Godwin58, GEMO59,60,61, O M Sinilnikova59,60, L Barjhoux59,60, D Stoppa-Lyonnet61, V Moncoutier61, S Giraud59, C Cassini62,63, L Olivier-Faivre62,63, F RĂ©villion64, J-P Peyrat64, D Muller65, J-P Fricker65, H T Lynch66, E M John67, S Buys68, M Daly69, J L Hopper70, M B Terry71, A Miron72, Y Yassin72, D Goldgar73, Breast Cancer Family Registry37, C F Singer74, D Gschwantler-Kaulich74, G Pfeiler74, A-C Spiess74, Thomas v O Hansen75, O T Johannsson76, T Kirchhoff77, K Offit77, K Kosarin77, M Piedmonte78, G C Rodriguez79, K Wakeley80, J F Boggess81, J Basil82, P E Schwartz83, S V Blank84, A E Toland85, M Montagna86, C Casella87, E N Imyanitov88, A Allavena89, R K Schmutzler90, B Versmold90, C Engel91, A Meindl92, N Ditsch93, N Arnold94, D Niederacher95, H DeiĂler96, B Fiebig97, R Varon-Mateeva98, D Schaefer99, U G Froster100, T Caldes101, M de la Hoya101, L McGuffog49, A C Antoniou49, H Nevanlinna6, P Radice4,5 and J BenĂtez1,3 on behalf of CIMB
Isolation of chick retina cones and study of their diversity based on oil droplet colour and nucleus position
The chick retina has four morphological cone types that differ not only in shape, but also in the visual pigment in the outer segment, in the colour of the oil droplet in the inner segment and in synaptic connectivity. Neither the type of droplet nor the visual pigment has been definitively established for the four cone types. The main aim of the present work has been the isolation of entire live photoreceptors in order to study the oil droplet colour in each cone type and to quantify each type. We have improved an earlier retinal cell isolation method and obtained large numbers of entire cones. Principal cones (27% of the cones) possess a yellow or colourless droplet. Accessory cones (27% of the cones) all contain a small pale green droplet. Straight cones (44% of the cones) have a red, orange, yellow, or colourless droplet. Oblique cones (1.66% of the cones) all have a colourless droplet. We have found that straight cones with a red, orange, or yellow droplet differ in terms of the position of the nucleus and their percentage and conclude that they are distributed in three rows in the outer nuclear layer (ONL) of the central retina. Our study of 4,6-diamidino-2-phenylindole-stained retinal sections has revealed three rows of nuclei instead of the two currently thought to form the ONL. Together, our results show a larger cone diversity than previously known, suggest a larger functional diversity and provide an efficient method for isolating entire chick photoreceptors
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
Background: Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas
(EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis
and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and
sporadic ovarian tumours.
Methods: High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-
BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or
specific copy number features.
Results: Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their
BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis,
regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater
contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours.
Conclusion: Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring
in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of
clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitorsThis study was funded by the Fondo de InvestigacioÂŽn
Sanitaria (FIS), Instituto de Salud Carlos III (grants CP07/00113
and PS09/01094
- âŠ